Medium-sized Foreign Drug Makers Markeing Cancer Drugs in Japan

摘要

Medium-scale foreign drug companies are developing their businesses in Japan for cancer drugs,with plans to first make inroads into the domestic market with drugs for specific cancers that have yet to be offered in the country.In 2006,Schering-Plough K.K.began marketing in September its malignant glioma treatment Temodal;Janssen Pharma started sales in December of its multiple myeloma treatment Velcade;and Bayer Yakuhin submitted an application for approval of Nexavar to treat renal cell carcinoma.